| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis.
|
N Engl J Med
|
2006
|
9.93
|
|
2
|
Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in Latin American infants: a randomised, double-blind, placebo-controlled phase III study.
|
Lancet
|
2008
|
4.50
|
|
3
|
Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial.
|
Vaccine
|
2009
|
2.06
|
|
4
|
Single dose vaccination with AS03-adjuvanted H5N1 vaccines in a randomized trial induces strong and broad immune responsiveness to booster vaccination in adults.
|
Vaccine
|
2009
|
1.56
|
|
5
|
Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study.
|
Vaccine
|
2009
|
1.53
|
|
6
|
Immunogenicity and safety of AS03-adjuvanted 2009 influenza A H1N1 vaccine in children 6-35 months.
|
Vaccine
|
2010
|
1.40
|
|
7
|
Immunogenicity and tolerability of an AS03(A)-adjuvanted prepandemic influenza vaccine: a phase III study in a large population of Asian adults.
|
Vaccine
|
2009
|
1.30
|
|
8
|
Immunogenicity and Safety of H5N1 A/Vietnam/1194/2004 (Clade 1) AS03-adjuvanted prepandemic candidate influenza vaccines in children aged 3 to 9 years: a phase ii, randomized, open, controlled study.
|
Pediatr Infect Dis J
|
2010
|
1.27
|
|
9
|
Horizontal transmission of a human rotavirus vaccine strain--a randomized, placebo-controlled study in twins.
|
Vaccine
|
2011
|
1.21
|
|
10
|
Immunogenicity profile of a 3.75-μg hemagglutinin pandemic rH5N1 split virion AS03A-adjuvanted vaccine in elderly persons: a randomized trial.
|
J Infect Dis
|
2011
|
1.03
|
|
11
|
Live attenuated human rotavirus vaccine, RIX4414, provides clinical protection in infants against rotavirus strains with and without shared G and P genotypes: integrated analysis of randomized controlled trials.
|
Pediatr Infect Dis J
|
2009
|
0.98
|
|
12
|
Extended antigen sparing potential of AS03-adjuvanted pandemic H1N1 vaccines in children, and immunological equivalence of two formulations of AS03-adjuvanted H1N1 vaccines: results from two randomised trials.
|
BMC Infect Dis
|
2013
|
0.95
|
|
13
|
Aseptic meningitis: case definition and guidelines for collection, analysis and presentation of immunization safety data.
|
Vaccine
|
2007
|
0.94
|
|
14
|
A vaccine manufacturer's approach to address medical needs related to seasonal and pandemic influenza viruses.
|
Influenza Other Respir Viruses
|
2008
|
0.89
|
|
15
|
Immunogenicity and safety of a novel AS03(A)-adjuvanted H1N1 2009 pandemic influenza vaccine in adults in Japan.
|
Hum Vaccin
|
2010
|
0.89
|
|
16
|
Characterization and long-term persistence of immune response following two doses of an AS03A-adjuvanted H1N1 influenza vaccine in healthy Japanese adults.
|
Hum Vaccin Immunother
|
2012
|
0.85
|
|
17
|
Long-term persistence of humoral and cellular immune responses induced by an AS03A-adjuvanted H1N1 2009 influenza vaccine: an open-label, randomized study in adults aged 18-60 years and older.
|
Hum Vaccin Immunother
|
2013
|
0.85
|
|
18
|
Safety and immunogenicity of a split-virion AS03A-adjuvanted A/Indonesia/05/2005 (H5N1) vaccine in Taiwanese adults.
|
J Formos Med Assoc
|
2012
|
0.82
|
|
19
|
Phase II, randomized, open, controlled study of AS03-adjuvanted H5N1 pre-pandemic influenza vaccine in children aged 3 to 9 years: follow-up of safety and immunogenicity persistence at 24 months post-vaccination.
|
Influenza Other Respir Viruses
|
2015
|
0.78
|
|
20
|
Flexibility of interval between vaccinations with AS03A-adjuvanted influenza A (H1N1) 2009 vaccine in adults aged 18-60 and >60 years: a randomized trial.
|
BMC Infect Dis
|
2012
|
0.77
|
|
21
|
Cross-clade immunogenicity and antigen-sparing with an AS03(A)-adjuvanted prepandemic influenza vaccine in a Thai population.
|
J Med Assoc Thai
|
2011
|
0.75
|